To investigate the regulatory effect of Fanlian Huazhuo Formula on cholesterol metabolism disorder in mice with acute hyperlipidemia.Methods:An acute hyperlipidemia model was established in C57BL/6 mice using Triton-WR1339.After 5 days of treatment，serum levels of total cholesterol(TC)，triglycerides(TG)，low-density lipoprotein cholesterol(LDL-C)，high-density lipoprotein cholesterol(HDL-C)，glutamic oxalacetic transaminase(GOT)，and glutamic-pyruvic transaminase(GPT) were measured.Hematoxylin-eosin(HE) staining was used to observe pathological changes in the liver.Oil Red O staining was performed to detect lipid accumulation in the liver.Western blot was used to detect changes in the expression of asialoglycoprotein receptor 1(ASGR1)，liver X receptor α(LXRα)，ATP-binding cassette transporter A1(ABCA1)，ABCA5，and cytochrome P450 7A1(CYP7A1) in the liver.Results:Compared with the model group，Fanlian Huazhuo Formula significantly reduced serum levels of TC，TG，LDL-C，GOT，and GPT，increased HDL-C levels(all P<0.05)，significantly upregulated the protein expression levels of ABCA1，ABCG5，LXRα，and CYP7A1，significantly downregulated the protein expression level of ASGR1(all P<0.05)，significantly reduced lipid accumulation in hepatocytes，and improved liver pathology.Conclusion:Fanlian Huazhuo Formula may promote cholesterol efflux and reduce blood lipids in mice with acute hyperlipidemia by regulating the ASGR1/LXRα/CYP7A1 signaling pathway.